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Gp130 Cytokines Exert Differential Patterns
of Crosstalk in Adipocytes Both In Vitro
and In Vivo
Ursula A. White1, William C. Stewart2 and Jacqueline M. Stephens1
Glycoprotein 130 (Gp130) cytokines are involved in the regulation of numerous biological processes, including
hematopoiesis, immune response, inflammation, cardiovascular action, and neuronal survival. These cytokines
share gp130 as a common signal transducer in their receptor complex and typically activate signal transducer and
activator of transcription (STAT) 3. Studies have shown that several gp130 cytokines have differential effects on both
adipogenesis and insulin-stimulated glucose uptake. Yet, the complex interactions of these cytokines in adipose
tissue have not been studied. Gp130 cytokines are differentially regulated in multiple tissues due to the presence of
additional receptor components that are required for signaling, including the leukemia inhibitory factor receptor (LIFR).
Previous studies from our laboratory highlighted the ability of specific gp130 cytokines to crosstalk in adipocytes
that correlated with LIFR degradation. Crosstalk is defined as the ability of one cytokine to modulate the signaling
of another cytokine. Our novel studies reveal that white adipose tissue is highly responsive to gp130 cytokines, and
we provide the first evidence that these cytokines can exert inhibitory crosstalk in adipose tissue in vivo. Moreover,
several gp130 cytokines that use the LIFR, including cardiotrophin-1 (CT-1), LIF, and human oncostatin M (hOSM),
can alter the subsequent signaling of other family members in adipocytes both in vitro and in vivo. Our data also show
that murine OSM and neuropoietin do not crosstalk in the same manner as other gp130 cytokines, which likely results
from their inability to activate the LIFR. Overall, we have observed distinctive patterns of crosstalk signaling by gp130
cytokines in adipocytes in vitro and in vivo and demonstrate the crosstalk is not dependent on new protein synthesis
or extracellular-signal-regulated kinase activation.
Obesity (2011) 19, 903–910. doi:10.1038/oby.2010.293

Introduction

The Interleukin (IL)-6 family of cytokines is a group of functionally and structurally related proteins that consists of IL-6,
IL-11, IL-27, leukemia inhibitory factor (LIF), oncostatin M
(OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1
(CT-1), novel neurotrophin-1/B cell stimulating factor-3 or
cardiotrophin-like cytokine, and neuropoietin (NP) (reviewed
in ref. 1). The IL-6 cytokine family regulates a variety of complex
cellular processes, such as hematopoiesis, immune response,
inflammation, differentiation, mammalian reproduction, cardiovascular action, and neuronal survival (reviewed in ref. 2).
Signal transduction involves activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, typically activating STAT3 and, to a lesser extent, STAT1
(reviewed in ref. 2). In addition, glycoprotein 130 (gp130)
cytokines can also activate other signaling pathways, including
the mitogen-activated protein kinase (MAPK) cascade, PI3K
(phosphatidylinositol-3 kinase), mTOR (mammalian target of

rapamycin/p70 S6 kinase), and AMPK (5′ adenosine monophosphate-activated protein kinase) (reviewed in ref. 3).
Because all members of this family use gp130 as a common
signal transducer within their receptor complex for signaling,
the IL-6 family is commonly referred to as the gp130 cytokines
(reviewed in ref. 4). The shared usage of signal transducers in
the receptor complexes likely accounts for the functional redundancy of gp130 cytokines in mediating biological effects. In
addition, the ubiquitous expression of gp130 facilitates the pleiotropic nature of these cytokines. The differences in their activity
can be partially attributed to the use of additional receptor components that are used by these cytokines. IL-6 and IL-11 first
bind to the IL-6 receptor-α (5) and IL-11 receptor-α (6), respectively, and then the complex associates with a gp130 homodimer
complex for signaling. IL-27 engages a gp130/WSX-1 (a subunit
of the IL-27 receptor) heterodimeric receptor complex (7). LIF
and CT-1 require the gp130/LIF receptor (LIFR) complex to
mediate signal transduction (8,9). CT-1 has also been reported
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to recruit an α-receptor (10), which to date has not been characterized. OSM can alternatively use a gp130/OSM receptor
(OSMR) complex (11), and has also been reported to use the
LIFR (12). Both CNTF and cardiotrophin-like cytokine use a
signaling complex, including CNTFRα, gp130, and LIFR for
signal transduction (13,14). NP was also reported to use this
tripartite receptor complex (15); however, recent studies from
our laboratory demonstrate that NP-induced STAT3 activation
in adipocytes is not mediated by LIFR signaling (16).
In recent years, gp130 cytokines have been implicated as potential therapeutic targets in obesity (reviewed in ref. 3). Although
adipocytes are responsive to gp130 cytokines (17–22), the effects
of these cytokines on adipose tissue function is largely unknown.
Interestingly, some gp130 cytokines, like OSM and NP, can inhibit
adipogenesis (22–24), while others, such as LIF (25), CT-1 (21),
and CNTF (20), do not attenuate adipocyte differentiation. In
addition, CT-1 and NP have been reported to inhibit insulinstimulated glucose uptake (21,22), whereas LIF (25) and CNTF
(20) do not impair insulin action in adipocytes. Notably, both
CT-1 and LIF act through a signaling complex of LIFR/gp130, yet
these cytokines exert different effects on insulin action. Hence,
the mechanisms and signaling components involved in gp130
cytokine action are not fully understood.
Previous studies from our lab show that gp130 cytokines
have the unique ability to crosstalk with other members of the
gp130 family to attenuate one another’s signaling (26). Our
findings in cultured adipocytes indicate that this crosstalk is
correlated with the degradation of the LIFR via a lysosomemediated pathway (26). To summarize, these studies demonstrated that LIF, CT-1, and human OSM had profound effects
on LIFR degradation and supported the hypothesis that crosstalk among certain gp130 cytokines could be attributed to
decreased expression of the LIFR. To further understand the
signaling of this cytokine family, we have continued to investigate the crosstalk of gp130 cytokines in adipocytes in vitro
and in vivo. Our novel data demonstrate that white adipose
tissue (epididymal and retroperitoneal) is highly responsive
to several gp130 cytokines. We also provide the first evidence
of gp130 cytokine inhibitory crosstalk in adipose tissue in
vivo. Moreover, NP and murine OSM (mOSM) do not exert
the same inhibitory crosstalk that we have observed for CT-1
and LIF. Neither NP nor mOSM was capable of attenuating
the signaling of other gp130 cytokines. Recent findings from
our laboratory demonstrated that NP does not induce LIFR
activation (16). Our current studies indicate that the unique
crosstalk abilities of mOSM and NP can be attributed to their
inability to activate the LIFR. Collectively, our data show that
gp130 cytokines exert differential crosstalk signaling capabilities in both cultured adipocytes in vitro and adipose tissue in
vivo, and the inhibitory crosstalk is not dependent on new protein synthesis or the activation of MAPK.
Methods and Procedures
Materials
Dulbecco’s modified Eagle’s media was purchased from Sigma (St.
Louis, MO). Bovine and fetal bovine sera were purchased from Hyclone
904

(South Logan, Utah). Mouse recombinant NP, mouse recombinant
CT-1, and mouse recombinant OSM were all purchased from R&D
Systems (Minneapolis, MN). Recombinant human OSM was purchased
from Invitrogen (Carlsbad, CA), and mouse recombinant LIF was purchased from BD Transduction (Franklin Lakes, NJ). Cycloheximide
was purchased from Sigma. Both STAT3 and phospho-specific STAT3
(Y705) were monoclonal antibodies purchased from BD Transduction.
Both the MAPK (extracellular-signal-regulated kinases (ERKs) 1 and
2) and LIFR polyclonal antibodies and the peroxisome proliferator–
activated receptor-γ monoclonal antibody were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The polyclonal anti-active
MAPK (ERK1/2) antibody and U0126 inhibitor were purchased from
Promega (Madison, WI). Nitrocellulose was purchased from Bio-Rad
(Hercules, CA). The BCA kit and the enhanced chemiluminescence kit
were purchased from Thermo Scientific (Waltham, MA). Horseradish
peroxidase–conjugated secondary antibodies were purchased from
Jackson ImmunoResearch Laboratories (West Grove, PA).
Cell culture
Murine 3T3-L1 preadipocytes were plated and grown to 2 days
postconfluence in Dulbecco’s modified Eagle’s medium containing 10% bovine serum. Medium was changed every 48 h. Cells were
induced to differentiate by changing the medium to Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum, 0.5 mmol/l
3-isobutylmethylxanthine, 1 μmol/l dexamethasone, and 1.7 μmol/l
insulin. After 48 h, this medium was replaced with Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, and cells
were maintained in this medium until used for experimentation.
Preparation of whole cell extracts
Cell monolayers of 3T3-L1 adipocytes were harvested in a nondenaturing buffer containing 150 mmol/l NaCl, 10 mmol/l Tris pH 7.4, 1 mmol/l
(ethylenebis(oxyethylenenitrilo)) tetraacetic acid, 1 mmol/l EDTA, 1%
Triton-X 100, 0.5% Igepal CA-630, 1 μmol/l phenylmethylsulfonyl fluoride, 1 μmol/l pepstatin, 50 trypsin inhibitory milliunits of aprotinin,
10 μmol/l leupeptin, and 2 mmol/l sodium vanadate and frozen. Next,
the samples were thawed and centrifuged at 14,000g at 4 °C for 10 min.
Supernatants containing whole cell extracts were analyzed for protein
content using a BCA kit according to the manufacturer’s instructions.
Rodent adipose tissue isolation
Six-week-old Sprague–Dawley rats were euthanized by cervical dislocation, and tissues were immediately removed and frozen in liquid
nitrogen. Frozen tissues were homogenized in a buffer containing
150 mmol/l NaCl, 10 mmol/l Tris pH 7.4, 1 mmol/l EGTA, 1 mmol/l
EDTA, 1% Triton-X 100, 0.5% Igepal CA-630, 1 μmol/l phenylmethylsulfonyl fluoride, 1 μmol/l pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 μmol/l leupeptin, and 2 mmol/l sodium vanadate.
Homogenates were centrifuged for 10 min at 6,500g to remove any
debris and insoluble material and then analyzed for protein content. All
animal studies were carried out with protocols that were reviewed and
approved by institutional animal care and use committees.
Gel electrophoresis and western blot analysis
Proteins were separated in 7.5% polyacrylamide (acrylamide from
National Diagnostics) gels containing sodium dodecyl sulfate (SDS)
according to Laemmli (27) and transferred to nitrocellulose membrane
in 25 mmol/l Tris, 192 mmol/l glycine, and 20% methanol. Following
transfer, the membrane was blocked overnight in 4% milk at 4 °C.
Results were visualized with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence.
Results

Although studies have shown that cultured adipocytes are
responsive to gp130 cytokines (17–22,25), the responsiveness
VOLUME 19 NUMBER 5 | May 2011 | www.obesityjournal.org

articles
Adipocyte Biology
a

RP
S

C

Epi
L

S

C

BAT
L

S

C

Sk Mus
L

S

C

Liver
L

C

L

15 min treatment

92 kda

STAT3 Tyr705

44 kda
42 kda

Active MAPK

44 kda

MAPK

b

RP
S

Epi

N O

S

N

BAT
O

S

N

Sk Mus
O

S

N

O

Liver
N

O

15 min treatment

92 kda

STAT3 Tyr705

44 kda
42 kda

Active MAPK

44 kda

MAPK

c
190 kda

44 kda

RP

Epi BAT Mus Liv
LIFR

MAPK

Figure 1 The responsiveness to glycoprotein 130 (gp130) cytokines
in insulin sensitive tissues in vivo. Six-week-old male Sprague–Dawley
rats were given an intraperitoneal injection of (a) vehicle (saline) control,
cardiotrophin-1 (0.1 μg/g animal), and leukemia inhibitory factor (LIF)
(0.1 μg/g animal) or (b) vehicle (saline) control, neuropoietin (0.1 μg/g
animal), and murine oncostatin M (mOSM) (0.1 μg/g animal). Fifteen
min after the injection the rats were killed and the retroperitoneal
(RP), epididymal (Epi), brown adipose tissue (BAT), skeletal muscle
(Sk Mus), and liver extracts were immediately removed and frozen in
liquid nitrogen. 220 μg of epididymal, retroperitoneal, and BAT extracts
and 440 μg of Sk Mus and liver extracts were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to nitrocellulose, and subjected to western blot analysis.
This is a representative experiment independently performed three
times. (c) Tissue extracts from these rats given only a vehicle (saline)
injection were used to examine LIF receptor expression. 200 μg of each
extract was separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to western blot analysis. This is a representative experiment
independently performed two times. STAT, signal transducer and
activator of transcription; MAPK, mitogen-activated protein kinase.

of these cytokines in vivo has not been investigated. Hence,
we examined the ability of several gp130 cytokines to induce
STAT3 and ERK phosphorylation in insulin sensitive tissues.
Tissue samples were extracted from Sprague–Dawley rats
20 min after an intraperitoneal injection with either vehicle
(saline), CT-1, LIF, NP, or OSM. As shown in Figure 1a,b,
CT-1, LIF, NP, and OSM potently induce both STAT3 tyrosine
phosphorylation and ERKs 1 and 2 activation in retroperitoneal and epididymal adipose tissue. We did not observe similar effects in brown adipose tissue, skeletal muscle, or liver. It
should be noted that we used twice as much protein for our
analysis of skeletal muscle and liver. These data indicate that
gp130 signaling is robust in white adipose tissue as compared
to other insulin sensitive tissues. MAPK protein levels are
shown to demonstrate even protein loading. Since all of the
obesity | VOLUME 19 NUMBER 5 | May 2011

g130 cytokines used in this experiment have been reported to
act via LIFR signaling (reviewed in ref. 2), we examined LIFR
expression in these tissues. As shown in Figure 1c, a substantial amount of the LIFR was present in each tissue. MAPK
protein levels are shown to demonstrate even protein loading.
Therefore, the varied responsiveness of the tissues to gp130
cytokines could not be explained by reduced LIFR expression.
Previous studies from our laboratory demonstrated that LIF,
CT-1 and OSM have the ability to crosstalk with one another in
a manner that resulted in the attenuation of subsequent signaling (26). We have recently reported the most newly identified
gp130 cytokine, NP, can activate STAT3 tyrosine phosphorylation in adipocytes both in vitro and in vivo (22). Hence, we
examined the ability of NP to modulate the signaling of other
gp130 cytokines. Of note, our previous crosstalk studies were
performed using human oncostatin M (hOSM). Evidence shows
that mOSM signals differently from hOSM in murine cells and
uses the OSM receptor β (11) as opposed to LIFR, which is used
by hOSM (16). In short, hOSM signals via the LIFR and not via
OSM receptor β (11,16). To study the crosstalk capabilities of
these cytokines, we examined the ability of LIF, CT-1, and NP
pretreatments to affect the acute actions of LIF, CT-1, NP, and
mOSM. In these experiments, fully differentiated 3T3-L1 adipocytes were pretreated with different gp130 cytokines for 6 h
followed by an acute 10 min treatment with CT-1, LIF, mOSM,
or NP. To ensure the efficacy of each cytokine, the activation
of STAT3 Tyr705 was observed in the absence of any pretreatment. As shown in Figure 2a,b, a 6-h pretreatment with CT-1
or LIF completely blocked the STAT3 tyrosine phosphorylation
induced by a 10-min treatment of CT-1, LIF, or NP, but did not
attenuate mOSM signaling. The same pattern of inhibition was
observed for MAPK (ERKs 1 and 2) activation. In contrast to
CT-1 and LIF, the results in Figure 2c indicate that NP pretreatment did not crosstalk with or inhibit the action of any of the
other gp130 cytokines. Taken together, these studies show that
several gp130 cytokines have the ability to block NP signaling,
but NP does not inhibit the signaling of any other gp130 family members. MAPK protein levels are shown to demonstrate
even loading in each experiment. As shown in Figure 2d, we
observed crosstalk at various periods of time. A 3, 8, or 24-h
pretreatment with LIF resulted in an inhibition of subsequent
CT-1 signaling, as shown by decreased STAT3 phosphorylation.
We also obtained the same results at 4 h, 12 h, and 18 h (data not
shown). These results indicate that gp130 cytokines exert inhibitory crosstalk over various pretreatment times. STAT3 protein
levels are shown to demonstrate even loading.
The results in Figure 2 and previous studies (26) demonstrate that the gp130 cytokines CT-1, LIF, and hOSM crosstalk
to inhibit one another’s signaling. Our current studies indicate that NP and mOSM have distinct crosstalk capabilities.
To further examine the distinct crosstalk abilities of mOSM
and hOSM, we pretreated cells with LIF or CT-1 for 6 h, and
then examined the induction of STAT3 tyrosine phosphorylation by hOSM and mOSM. As shown in Figure 3a, human,
but not murine, OSM signaling was attenuated by CT-1 and
LIF. Similar studies were performed to examine the crosstalk
905
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Figure 2 Crosstalk of glycoprotein 130 (gp130) cytokines in 3T3L1 adipocytes. Fully differentiated 3T3-L1 adipocytes received no
pretreatment (CTL, control) or were preincubated with 1 nmol/l
cardiotrophin-1 (CT-1) (a), 1 nmol/l leukemia inhibitory factor (LIF) (b,d),
or 1 nmol/l neuropoietin (NP) (c) for 3 h, 6 h, 8 h, or 24 h Next, the cells
were treated for 10 min with 1 nmol/l CT-1, 1 nmol/l LIF, 1 nmol/l murine
oncostatin M (mOSM), or 1 nmol/l NP. After the acute treatment, whole
cell extracts were prepared and 150 µg of each extract was separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis,
transferred to nitrocellulose, and subjected to western blot analysis.
The data in d is generated from the same exposure of the same blot.
This is a representative experiment performed independently four times.
MAPK, mitogen-activated protein kinase; STAT, signal transducer and
activator of transcription.

capabilities of OSM and NP. In these experiments, 3T3-L1 adipocytes were pretreated for 6 h with mOSM, hOSM or NP and
then exposed to NP, mOSM, or hOSM for 10 min. The data in
Figure 3b show that hOSM, but not mOSM, inhibited NP signaling, as evidenced by the decreased activation of STAT3 Tyr705
and MAPK. Conversely, NP did not attenuate either mOSM
or hOSM. Yet a NP pretreatment was capable of inhibiting NP
action. MAPK protein levels are shown to demonstrate even
loading.To determine whether crosstalk of gp130 cytokines
occurs in vivo, we injected Sprague–Dawley rats with vehicle
(saline), CT-1, or LIF, with or without an 8-h preinjection of
LIF. The animals were killed 15 min following the second injection. As shown in Figure 4a,b, both a CT-1 and a LIF injection
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Figure 3 Neuropoietin (NP) and murine oncostatin M (mOSM) have
distinct crosstalk abilities compared to other glycoprotein 130 cytokines
in 3T3-L1 adipocytes. (a) Fully differentiated 3T3-L1 adipocytes were
pretreated with 1 nmol/l cardiotrophin (CT) or 1 nmol/l leukemia inhibitory
factor (LIF) for 6-h. Next, the cells were treated for 10 min with 1 nmol/l
mOSM, or 1 nmol/l human oncostatin M (hOSM). (b) Fully differentiated
3T3-L1 adipocytes were pretreated with 1 nmol/l mOSM, 1 nmol/l hOSM,
or 1 nmol/l NP for 6 h. Next, the cells were treated for 10 min with 1 nmol/l
mOSM, 1 nmol/l hOSM, or 1 nmol/l NP. After the treatment, whole cell
extracts were prepared, and 160 µg of each extract was separated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, transferred
to nitrocellulose, and subjected to western blot analysis. Each figure is a
representative experiment performed independently three times. MAPK,
mitogen-activated protein kinase; STAT, signal transducer and activator
of transcription.

induced the activation of STAT3 Tyr705 and MAPK in the epididymal and retroperitoneal adipose tissues. However, a preinjection with LIF inhibited the STAT3 tyrosine phosphorylation
of both CT-1 and LIF in white adipose tissue. This is the first
in vivo demonstration that LIF can inhibit the action of CT-1.
The activation of ERKs 1 and 2 was also attenuated. STAT3 and
MAPK protein levels are shown to demonstrate even loading.
In addition to observing the interaction of CT-1 and LIF
signaling in vivo, we examined the crosstalk signaling of NP
and mOSM in adipose tissue. Although we have shown that
NP can induce STAT3 tyrosine phosphorylation in fat tissue in
vivo (22), the interaction of NP with other gp130 cytokines has
not been previously observed in vitro or in vivo. In this study,
rats were injected with vehicle (saline), NP, or mOSM, with
or without a 5-h preinjection of NP. The animals were killed
20 min following the second injection. As shown in Figure 4c,
both a NP and a mOSM injection induced the activation of
STAT3 Tyr705 in retroperitoneal adipose tissue. Our data indicate that a NP pretreatment did not inhibit the mOSM induction of STAT3 tyrosine phosphorylation. Yet, the NP-induced
VOLUME 19 NUMBER 5 | May 2011 | www.obesityjournal.org
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Figure 4 Leukemia inhibitory factor (LIF) treatment in vivo blocks
subsequent cardiotrophin-1 (CT-1) and LIF signaling, but neuropoietin
(NP) does not inhibit murine oncostatin M (mOSM) in rodent fat pads.
Six week old male Sprague–Dawley rats were given an intraperitoneal
injection of vehicle (saline) control, CT-1 (0.1 μg/g animal), or LIF
(0.1 μg/g animal), following at 8-h preinjection of saline (S) or LIF.
Fifteen min after the second injection the rats were killed and both
(a) retroperitoneal and (b) epididymal fat pads were immediately
removed and frozen in liquid nitrogen. 220 μg of retroperitoneal and
350 μg of epididymal tissue extract were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), transferred
to nitrocellulose, and subjected to western blot analysis. The data in
each figure is generated from the same exposure of the same blot.
Each figure is a representative experiment independently performed
three times. (c) Six week old male Sprague–Dawley rats were given
an intraperitoneal injection of vehicle (saline) control, NP (0.1 μg/g
animal), or mOSM (.1 μg/g animal), with or without a 5-h preinjection of
NP. Twenty min after the second injection the rats were killed and the
retroperitoneal fat pad was immediately removed and frozen in liquid
nitrogen. 150 μg of retroperitoneal tissue extract was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to western blot
analysis. This is a representative experiment independently performed
three times. MAPK, mitogen-activated protein kinase; STAT, signal
transducer and activator of transcription.

STAT3 Tyr705 was abolished. These findings correlate with our
in vitro data (Figure 2c). Similar observations were shown in
epididymal fat pads (data not shown). MAPK protein levels are
shown to demonstrate even loading.
The mechanisms underlying the crosstalk of gp130 cytokines
have not been elucidated. Hence, we examined the ability of
ERK phosphorylation and new protein synthesis to contribute
obesity | VOLUME 19 NUMBER 5 | May 2011

Figure 5 Crosstalk of glycoprotein 130 cytokines is not dependent
on new protein synthesis. Fully differentiated 3T3-L1 adipocytes were
pretreated with 1 nmol/l cardiotrophin-1 (CT-1) or 1nmol/l leukemia
inhibitory factor (LIF) for 4-h in the presence or absence of a 30 min
5 μmol/l cycloheximide preincubation. The cells were then treated (+) for
10 min with 1 nmol/l CT-1. After the treatment, whole cell extracts were
prepared and 150 µg of each extract was separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, transferred to nitrocellulose,
and subjected to western blot analysis. This is a representative
experiment performed independently four times. MAPK, mitogenactivated protein kinase, PPAR, peroxisome proliferator-activated
receptor.

to the observed interactions among gp130 cytokines. Numerous
studies have shown that gp130 cytokines induce the expression
of suppressors of cytokine signaling (SOCS) proteins (reviewed
in ref. 2), and we have observed the ability of these cytokines to
induce SOCS-3 mRNA in cultured fat cells (21–22,25). SOCS
are known to negatively regulate cytokine signal transduction,
and their induction is dependent on new protein synthesis. To
determine whether the inhibitory crosstalk exerted by gp130
cytokines could be a result of newly synthesized proteins, fully
differentiated 3T3-L1 adipocytes were pretreated with CT-1 or
LIF in the presence or absence of cycloheximide, an inhibitor of
protein synthesis. Next, the cells were acutely (10 min) exposed
to CT-1. Adipocytes with no pretreatment were observed to
show the efficacy of CT-1 signaling. As indicated in Figure 5,
the same pattern of crosstalk was observed in the presence
or absence of cycloheximide. Both CT-1 and LIF blocked the
signaling of an acute CT-1 treatment, as evidenced by a substantial decrease in STAT3 Tyr705 and MAPK activation. Both
STAT3 and MAPK protein levels are shown to demonstrate
even loading. The expression of peroxisome proliferator–activated receptor-γ, a labile transcription factor, is included to
show efficacy of the cycloheximide.
In addition to the JAK/STAT pathway, gp130 cytokines can
also activate the MAPK cascade (ERKs 1 and 2) (reviewed in
ref. 2). To assess whether the crosstalk of gp130 family members is dependent on the activation of ERKs 1 and 2, fully differentiated 3T3-L1 adipocytes were pretreated with CT-1, NP,
or LIF in the presence or absence of U0126, a selective ERK
1 and 2 inhibitor. Next, cells were exposed to an acute treatment with LIF or NP. The efficacy of both LIF and NP signaling
was observed in adipocytes with no pretreatment. As shown in
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Figure 6 Crosstalk of glycoprotein 130 cytokines is not dependent on the activation of MAPK. Fully differentiated 3T3-L1 adipocytes were pretreated
with 1 nmol/l cardiotrophin-1 (CT-1), 1 nmol/l leukemia inhibitory factor (LIF), or 1 nmol/l NP for 3-h in the presence or absence of a 30 min 5 μmol/l
U0126 preincubation. The cells were then treated (+) for 10 min with (a,b) 1 nmol/l LIF or (c,d) 1 nmol/l neuropoietin (NP). After the treatment, whole
cell extracts were prepared, and 150 µg of each extract was separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, transferred
to nitrocellulose, and subjected to western blot analysis. This is a representative experiment performed independently three times. MAPK, mitogenactivated protein kinase; STAT, signal transducer and activator of transcription.

Figure 6a,b, the ability of CT-1 and LIF to inhibit LIF signaling
is independent of the presence of active ERKs 1 and 2. Also, as
shown above, NP was incapable of inhibiting LIF action. An
analysis of NP signaling in Figure 6c,d confirms that NP can
be inhibited by CT-1 and LIF, and this crosstalk is unaffected
by the ability to activate ERK. In each experiment, STAT3 and
MAPK protein levels are shown to demonstrate even loading.
The efficacy of the U0126 inhibitor was validated by the inhibition in ERK phosphorylation.
Discussion

Although an understanding of the production, secretion,
function, and mechanisms underlying the actions of gp130
cytokines have not been fully elucidated, it is known that several of these family members are measurable in circulation in
humans (28–34). In addition, all gp130 cytokines activate the
JAK/STAT pathway, and many also activate the MAPK (ERK)
pathway. Previous studies from our laboratory highlighted the
crosstalk of several gp130 cytokines in cultured adipocytes,
which correlated with their ability to induce LIFR degradation.
In these follow-up studies, we further explored the crosstalk
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of gp130 cytokines both in vitro and in vivo. Our novel observations demonstrate that white adipose tissue is highly sensitive to LIF, CT-1, NP, and OSM in a manner not shared by
other insulin responsive tissues. In addition, we provide the
first demonstration of gp130 cytokine inhibitory crosstalk
in vivo. Overall, our results indicate that three gp130 family
members—CT-1, LIF, and hOSM—exert inhibitory crosstalk
both in vitro and in vivo. Moreover, this crosstalk is independent of the activation of ERKs 1 and 2 or new protein synthesis.
Our findings also show that NP and mOSM lack the ability
to crosstalk with other gp130 cytokines that are known LIFR
activators.
A common feature of many gp130 cytokines is their shared
use of not only gp130, but also LIFR proteins as components
of their receptor complex. Our data support the idea that the
crosstalk signaling may be due to differential usage of receptor
components. Studies have shown that treatment with gp130
cytokines, including CT-1, LIF, and hOSM, results in LIFR
internalization and degradation (26,35,36). Moreover, certain
gp130 family members that use the LIFR crosstalk with one
another in an antagonistic fashion, and this correlates with
VOLUME 19 NUMBER 5 | May 2011 | www.obesityjournal.org
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LIFR phosphorylation and degradation. Hence, this loss of
LIFR from the plasma membrane appears to account for the
inhibition of subsequent signaling by gp130 cytokines following an initial treatment.
Although NP was originally characterized as a cytokine
that required the LIFR for signal transduction (15), our recent
studies indicate that NP does not induce the phosphorylation
or degradation of the LIFR in the same manner as other gp130
cytokines in adipocytes (16). Hence, these observations suggest that NP does not crosstalk and inhibit the signaling of
other gp130 cytokines because it does not activate the LIFR.
Because NP propagates its signal through the JAK/STAT and
MAPK pathways in a manner similar to other gp130 cytokines,
our data suggest that the lack of signal inhibition may reside at
the level of the receptor. We postulate that NP uses a unique
signal transducer in its receptor complex, in addition to gp130.
Although we do not know the identity of this NP receptor(s),
our data clearly indicate that the LIFR is not involved (16).
Conversely, the unique crosstalk capabilities of mOSM can
be readily hypothesized. Because this cytokine activates the
OSM receptor β, it does not attenuate the signaling of gp130
cytokines that use the LIFR. This data is supported by studies
of hOSM, which activates the murine LIFR (16) and can crosstalk with CT-1 and LIF (26). Our studies with mOSM also support the notion that NP likely interacts with a novel receptor
that associates with gp130. A confounding observation is that
several gp130 cytokines can block the signaling of NP (Figures
2 and 3b). These data indicate that LIFR activating cytokines
can inhibit the action of NP, a gp130 cytokine that does not use
the LIFR. In summary, our studies show that LIFR activating
cytokines (LIF, CT-1, hOSM) are capable of inhibitory crosstalk with one another. Notably, these LIFR activating cytokines
can also inhibit NP, whose signaling is independent of LIFR
phosphorylation. NP pretreatment can attenuate NP signaling,
but does not inhibit the action of other LIFR or OSM receptor
β using cytokines.
Although the mechanisms underlying the crosstalk of
gp130 cytokines are poorly understood, our studies indicate
that two important factors, new protein synthesis and ERKs 1
and 2 activation, do not contribute to crosstalk among these
cytokines. It is well-established that the expression of SOCS
family members is highly induced by many different cytokines
and these proteins are known to interfere with subsequent
signaling via a classic negative feedback inhibition loop
(reviewed in ref. 37). Many gp130 cytokines induce SOCS-3
expression, and LIF, CT-1, NP, and OSM induce SOCS-3
mRNA in adipocytes (21,22,25,38). The role of SOCS proteins, if any, in the crosstalk of gp130 cytokines is unknown.
Nonetheless, our current studies clearly demonstrate that
gp130 inhibitory crosstalk is not dependent on newly synthesized proteins (Figure 5) and suggests that SOCS proteins
may not be involved. The activation of MAPK (ERKs 1 and
2) by gp130 cytokines can play important roles in cellular
actions. However, our data show that the inhibitory crosstalk
among several gp130 cytokines is not dependent on ERKs 1
and 2 activation (Figure 6).
obesity | VOLUME 19 NUMBER 5 | May 2011

To our knowledge, no other laboratories have investigated the
interactions of gp130 cytokines in vivo. Our data indicate that
gp130 family members crosstalk in vivo in the same manner as
in vitro. Hence, these effects are likely very important in white
adipose tissue since it is highly responsive to gp130 cytokine
exposure (Figure 1). LIF pretreatment inhibited both LIF and
CT-1 subsequent treatments in vitro and in vivo (Figures 2 and
4). This is the first evidence to show that a gp130 cytokine can
exert negative inhibitory crosstalk in vivo. CT-1 pretreatment
inhibited the signaling of CT-1 and LIF in vitro and in vivo
(data not shown). In addition, NP pretreatment had no effect
on an acute treatment of mOSM in vitro or in vivo (Figures 2
and 4). The fact that gp130 cytokines not only activate signaling pathways in vivo, but also inhibit subsequent signaling of
other gp130 family members confirms that a detailed analysis
of crosstalk mechanisms is relevant for a more in-depth perspective of gp130 cytokine secretion and action. In addition,
circulating levels of many gp130 cytokines have been examined
in humans and shown to have divergent effects on metabolism.
Recent studies suggest that CT-1 is produced from adipose
tissue, and may be modulated in obesity (28,29). Numerous
studies have also shown that IL-6 levels are greatly elevated in
obese individuals and strongly correlated with increased BMI
(32,39,40). Increased serum concentrations of other gp130
cytokines, such as LIF and OSM, are also associated with
metabolic abnormalities (30,31). Therefore, it is necessary to
understand the functions and interactions of these cytokines,
as well as the inhibitory crosstalk that gp130 cytokines exert
on their respective family members. Collectively, our data provide a basis for future analyses of cytokine interaction, and we
speculate that these interactions may greatly affect the physiological action of these cytokines, which can modulate both
adipocyte development and insulin action. Nonetheless, further studies are needed to examine how these processes could
possibly contribute to or affect metabolic disease states that are
characterized by the expression of multiple STAT3 activating
cytokines, including those belonging to the gp130 family.
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